{"classes":[{"categories":[{"measurements":[{"comment":"Upper and lower limits of 95% CI were not estimable due to the smaller number of participants with the event.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"groupId":"OG001","lowerLimit":"0.05","upperLimit":"0.28","value":"0.17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"SRE was defined as pathological bone fracture, initiation of radiotherapy or surgery on bone, spinal cord compression, or hypercalcemia of malignancy (HCM). SRE was assessed by centrally read radiographic bone surveys.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 4 mg or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes every 12 weeks for up to 96 weeks based on the participants most recent urine NTx measurement ( \\<50 nmol/mmol creatinine).","id":"OG000","title":"Zoledronic Acid Every 12 Weeks"},{"description":"Participants received 4 mg or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes every 4 weeks or every 12 weeks for up to 96 weeks based on the participants most recent urine NTx measurement (≥ 50 nmol/mmol creatinine or \\<50 nmol/mmol creatinine, respectively).","id":"OG001","title":"Zoledronic Acid Every 4 Weeks or 12 Weeks"}],"paramType":"NUMBER","populationDescription":"ITT analysis set included all participants who were enrolled in this study.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Percentage of Participants With ≥1 SRE at the End of 1 Year on Study","type":"PRIMARY","unitOfMeasure":"percentage of participants"}